Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview.

ABSTRACT: Patients with hepatocellular carcinoma (HCC) face a common type of cancer, which is amongst the most deadly types of cancer worldwide. The therapeutic options range from curative resection or ablation to loco regional therapies in palliative setting and last but not least, systemic treatment. The latter group underwent major changes in the last decade and a half. Since the introduction of sorafenib in 2007, many other systemic treatments have been investigated. Most without success. It took more than ten years before lenvatinib could be added as alternative first-line treatment option. Just recently a new form of systemic treatment, immunotherapy, entered the field of therapeutic options in patients with HCC. Immune checkpoint inhibitors are becoming the new standard of care in patients wi

SUBMITTER: van Doorn DJ 

PROVIDER: S-EPMC7821931 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature